Dual-Site Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease.

Autor: Fricke C; Department of Neurology, University of Leipzig, Leipzig, Germany., Duesmann C; Department of Neurology, University of Leipzig, Leipzig, Germany., Woost TB; Department of Neurology, University of Leipzig, Leipzig, Germany.; Department of Psychiatry and Psychotherapy, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany., von Hofen-Hohloch J; Department of Neurology, University of Leipzig, Leipzig, Germany., Rumpf JJ; Department of Neurology, University of Leipzig, Leipzig, Germany., Weise D; Department of Neurology, University of Leipzig, Leipzig, Germany., Classen J; Department of Neurology, University of Leipzig, Leipzig, Germany.
Jazyk: angličtina
Zdroj: Frontiers in neurology [Front Neurol] 2019 Mar 07; Vol. 10, pp. 174. Date of Electronic Publication: 2019 Mar 07 (Print Publication: 2019).
DOI: 10.3389/fneur.2019.00174
Abstrakt: Abnormal oscillatory activity in the subthalamic nucleus (STN) may be relevant for motor symptoms in Parkinson's disease (PD). Apart from deep brain stimulation, transcranial magnetic stimulation (TMS) may be suitable for altering these oscillations. We speculated that TMS to different cortical areas (primary motor cortex, M1, and dorsal premotor cortex, PMd) may activate neuronal subpopulations within the STN via corticofugal neurons projecting directly to the nucleus. We hypothesized that PD symptoms can be ameliorated by a lasting decoupling of STN neurons by associative dual-site repetitive TMS (rTMS). Associative dual-site rTMS (1 Hz) directed to PMd and M1 ("ADS-rTMS") was employed in 20 PD patients treated in a blinded, placebo-controlled cross-over design. Results: No adverse events were noted. We found no significant improvement in clinical outcome parameters (videography of MDS-UPDRS-III, finger tapping, spectral tremor power). Variation of the premotor stimulation site did not induce beneficial effects either. A single session of ADS-rTMS was tolerated well, but did not produce a clinically meaningful benefit on Parkinsonian motor symptoms. Successful treatment using TMS targeting subcortical nuclei may require an intervention over several days or more detailed physiological information about the individual brain state and stimulation-induced subcortical effects.
Databáze: MEDLINE